## Richard J Macisaac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1465337/publications.pdf

Version: 2024-02-01

93792 5,744 150 39 citations h-index papers

g-index 151 6877 citing authors

97045

71

151 all docs

151 docs citations

times ranked

#	Article	IF	CITATIONS
1	Novel Therapies for Kidney Disease in People With Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1-e24.	1.8	9
2	Functional MRI in assessment of diabetic kidney disease in people with type 1 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108076.	1.2	4
3	A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes. Diabetes Care, 2022, 45, 194-203.	4.3	24
4	Role of the adaptive immune system in diabetic kidney disease. Journal of Diabetes Investigation, 2022, 13, 213-226.	1.1	21
5	Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial. Diabetes Care, 2022, 45, 381-390.	4.3	43
6	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care, 2022, 45, e888-e897.	4.3	20
7	Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys. Diabetes Technology and Therapeutics, 2022, 24, 350-356.	2.4	1
8	Exercise habits and glucose management among older adults with type $1$ diabetes using insulin pumps. Acta Diabetologica, 2022, , $1$ .	1.2	0
9	Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model. Physiological Reports, 2022, 10, e15257.	0.7	13
10	Closed-Loop Insulin Delivery Effects on Glycemia During Sleep and Sleep Quality in Older Adults with Type 1 Diabetes: Results from the ORACL Trial. Diabetes Technology and Therapeutics, 2022, 24, 666-671.	2.4	8
11	Insulin pump troubleshooting: a case vignette and systematic approach. Medical Journal of Australia, 2022, 216, 595-596.	0.8	2
12	Temporal trends in non-traumatic lower extremity amputations (LEAs) and their association with 12-month mortality in people with diabetes, 2004–2016. Journal of Diabetes and Its Complications, 2022, , 108221.	1.2	2
13	Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease. Diabetes/Metabolism Research and Reviews, 2022, 38, .	1.7	16
14	GripBMI – A fast and simple sarcopenia screening tool in post acute inpatient rehabilitation. Clinical Nutrition, 2021, 40, 1022-1027.	2.3	5
15	Sarcopenia Is Associated With Reduced Function on Admission to Rehabilitation in Patients With Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e687-e695.	1.8	4
16	Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes Technology and Therapeutics, 2021, 23, 460-466.	2.4	7
17	Performance of 4 Creatinine-based Equations in Assessing Glomerular Filtration Rate in Adults with Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e61-e73.	1.8	5
18	The prevalence of sarcopenia in middleâ€aged and older patients in postâ€acute inpatient rehabilitation: a crossâ€sectional study. JCSM Rapid Communications, 2021, 4, 16-23.	0.6	1

#	Article	IF	Citations
19	Evaluation of the diagnostic performance of the creatinineâ€based Chronic Kidney Disease Epidemiology Collaboration equation in people with diabetes: A systematic review. Diabetic Medicine, 2021, 38, e14391.	1.2	6
20	Reducing adverse events associated with the glucagon stimulation test for the assessment of growth hormone deficiency in adults with a high prevalence of pituitary hormone deficiencies. Clinical Endocrinology, 2021, 95, 125-133.	1.2	0
21	Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide. Future Cardiology, 2021, 17, 459-473.	0.5	4
22	Investigating the Neuroprotective Effect of Oral Omega-3 Fatty Acid Supplementation in Type 1 Diabetes (nPROOFS1): A Randomized Placebo-Controlled Trial. Diabetes, 2021, 70, 1794-1806.	0.3	23
23	Hospital admissions for cardiovascular complications of people with or without diabetes, Victoria, 2004–2016. Medical Journal of Australia, 2021, 215, 85-86.	0.8	4
24	Severe acute respiratory syndrome coronavirus 2 as a potential cause of type 1 diabetes facilitated by spike protein receptor binding domain attachment to human islet cells: An illustrative case study and experimental data. Diabetic Medicine, 2021, 38, e14608.	1.2	9
25	First Randomized Controlled Trial of Hybrid Closed Loop Versus Multiple Daily Injections or Insulin Pump Using Self-Monitoring of Blood Glucose in Free-Living Adults with Type 1 Diabetes Undertaking Exercise. Journal of Diabetes Science and Technology, 2021, 15, 1399-1401.	1.3	9
26	Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial. Diabetes Care, 2021, 44, 2371-2378.	4.3	22
27	Reply – Letter to the editor. Clinical Nutrition, 2021, 40, 4822-4823.	2.3	0
28	Meal-time glycaemia in adults with type $1$ diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Research and Clinical Practice, 2021, 179, 109000.	1.1	3
29	Omega-3 polyunsaturated fatty acid oral supplements for improving peripheral nerve health: a systematic review and meta-analysis. Nutrition Reviews, 2020, 78, 323-341.	2.6	20
30	Reducing glucose variability with continuous subcutaneous insulin infusion is associated with reversal of axonal dysfunction in type 1 diabetes mellitus. Muscle and Nerve, 2020, 61, 44-51.	1.0	4
31	Diabetes and higher HbA1c levels are independently associated with adverse renal outcomes in inpatients following multiple hospital admissions. Journal of Diabetes and Its Complications, 2020, 34, 107465.	1.2	4
32	Effect of angiotensin II receptor blocker and salt supplementation on short-term blood pressure variability in type 2 diabetes. Journal of Human Hypertension, 2020, 34, 143-150.	1.0	1
33	Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility. Diabetes, 2020, 69, 83-98.	0.3	48
34	Clinicians feel comfortable discussing alcohol but not illicit drug use with young adults with Type 1 diabetes: a survey of clinicians. Diabetic Medicine, 2020, 37, 1076-1078.	1.2	4
35	Impact of type 2 diabetes on hospitalization and mortality in people with malignancy. Diabetic Medicine, 2020, 37, 362-368.	1.2	5
36	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations. Contemporary Clinical Trials, 2020, 90, 105892.	0.8	29

#	Article	IF	CITATIONS
37	Effect of Salt Supplementation on Sympathetic Activity and Endothelial Function in Salt-Sensitive Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1187-e1200.	1.8	6
38	Glucose and Counterregulatory Responses to Exercise in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia Using Closed-Loop Insulin Delivery: A Randomized Crossover Study. Diabetes Care, 2020, 43, 480-483.	4.3	19
39	Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care, 2020, 43, 3024-3033.	4.3	85
40	Baseline liver function tests and full blood count indices and their association with progression of chronic kidney disease and renal outcomes in Aboriginal and Torres Strait Islander people: the eGFR follow- up study. BMC Nephrology, 2020, 21, 523.	0.8	5
41	Utility of adrenocorticotropic hormone in adrenal vein sampling despite the occurrence of discordant lateralization. Clinical Endocrinology, 2020, 93, 394-403.	1.2	16
42	COVID-19, Type 1 Diabetes Clinical Practice, Research, and Remote Medical Care: A View From the Land Down-Under. Journal of Diabetes Science and Technology, 2020, 14, 803-804.	1.3	11
43	Differential effects of vagus nerve stimulation strategies on glycemia and pancreatic secretions. Physiological Reports, 2020, 8, e14479.	0.7	18
44	Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?. Diabetes Therapy, 2020, 11, 1627-1638.	1.2	8
45	Reduced Exercise Capacity in Diabetes Mellitus Is Not Associated with Impaired Deformation or Twist. Journal of the American Society of Echocardiography, 2020, 33, 481-489.	1.2	10
46	Alcohol and illicit drug use in people with diabetes. Lancet Diabetes and Endocrinology, the, 2020, 8, 239-248.	5.5	18
47	The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia. Journal of Clinical Medicine, 2020, 9, 1091.	1.0	6
48	The association between maternal renal function and pregnancy outcomes in type 1 and type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 165, 108225.	1.1	4
49	Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study. Diabetes Technology and Therapeutics, 2019, 21, 499-506.	2.4	25
50	Progression of Diabetic Kidney Disease in the Absence of Albuminuria. Diabetes Care, 2019, 42, 1842-1844.	4.3	21
51	SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3077-3087.	1.8	74
52	Changes in soluble tumor necrosis factor receptor typeÂ1 levels and early renal function decline in patients with diabetes. Journal of Diabetes Investigation, 2019, 10, 1537-1542.	1.1	8
53	Sildenafil enhances central hemodynamic responses to exercise, but not Vi‡ <scp>o</scp> <sub>2peak</sub> , in people with diabetes mellitus. Journal of Applied Physiology, 2019, 127, 1-10.	1.2	1
54	Is hyperfiltration associated with higher urine albumin-to-creatinine ratio at follow up among Indigenous Australians? The eGFR follow-up study. Journal of Diabetes and Its Complications, 2019, 33, 343-349.	1.2	6

#	Article	IF	CITATIONS
55	Diagnostic performance of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at estimating glomerular filtration rate in adults with diabetes mellitus: a systematic review and meta-analysis protocol. BMJ Open, 2019, 9, e031558.	0.8	12
56	Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2019, 21, 56-58.	2.4	22
57	Inflammatory proteins in diabetic kidney diseaseâ€"potential as biomarkers and therapeutic targets. Annals of Translational Medicine, 2019, 7, S243-S243.	0.7	3
58	Systematic review and meta-analysis of prevalence of sarcopenia in post acute inpatient rehabilitation. Osteoporosis International, 2018, 29, 805-812.	1.3	61
59	Pathophysiological Links Between Diabetes and Blood Pressure. Canadian Journal of Cardiology, 2018, 34, 585-594.	0.8	38
60	Diagnosis and Significance of Pulmonary Microvascular Disease in Diabetes. Diabetes Care, 2018, 41, 854-861.	4.3	24
61	High Baseline Levels of Tumor Necrosis Factor Receptor 1 Are Associated With Progression of Kidney Disease in Indigenous Australians With Diabetes: The eGFR Follow-up Study. Diabetes Care, 2018, 41, 739-747.	4.3	32
62	Effects of Diabetes Medications Targeting the Incretin System on the Kidney. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 321-323.	2.2	11
63	Experiences of young adults with type 1 diabetes while using alcohol and recreational drugs: An interpretative phenomenological analysis (IPA) of semi-structured interviews. Diabetes Research and Clinical Practice, 2018, 141, 47-55.	1.1	9
64	Glycemic Control as Primary Prevention for Diabetic Kidney Disease. Advances in Chronic Kidney Disease, 2018, 25, 141-148.	0.6	26
65	Trajectories of eGFR decline over a four year period in an Indigenous Australian population at high risk of CKD-the eGFR follow up study. Clinical Biochemistry, 2018, 53, 58-64.	0.8	3
66	Contribution of cardiometabolic risk factors to estimated glomerular filtration rate decline in <scp>I</scp> ndigenous <scp>A</scp> ustralians with and without albuminuria ―the eGFR Followâ€up Study. Nephrology, 2018, 23, 682-689.	0.7	5
67	Relationship between urinary sodiumâ€toâ€potassium ratio and ambulatory blood pressure in patients with diabetes mellitus. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 94-97.	0.9	4
68	Crossâ€sectional associations of albuminuria among Aboriginal and Torres Strait Islander adults: the eGFR Study. Nephrology, 2018, 23, 37-45.	0.7	6
69	Use of Readily Accessible Inflammatory Markers to Predict Diabetic Kidney Disease. Frontiers in Endocrinology, 2018, 9, 225.	1.5	38
70	Exercise capacity in diabetes mellitus is predicted by activity status and cardiac size rather than cardiac function: a case control study. Cardiovascular Diabetology, 2018, 17, 44.	2.7	30
71	Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 2018, 8, e020274.	0.8	7
72	Asymmetric changes in circulating insulin levels after an increase compared with a reduction in insulin pump basal rate in people with Type 1 diabetes. Diabetic Medicine, 2017, 34, 1158-1164.	1.2	2

#	Article	IF	Citations
73	Closed-Loop Insulin Delivery for Adults with Type 1 Diabetes Undertaking High-Intensity Interval Exercise Versus Moderate-Intensity Exercise: A Randomized, Crossover Study. Diabetes Technology and Therapeutics, 2017, 19, 340-348.	2.4	59
74	"It Is Definitely a Game Changer― A Qualitative Study of Experiences with In-home Overnight Closed-Loop Technology Among Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 410-416.	2.4	28
75	Bilirubin concentration is positively associated with haemoglobin concentration and inversely associated with albumin to creatinine ratio among Indigenous Australians: eGFR Study. Clinical Biochemistry, 2017, 50, 1040-1047.	0.8	6
76	Clinical predictive factors in diabetic kidney disease progression. Journal of Diabetes Investigation, 2017, 8, 6-18.	1.1	133
77	Long-term intra-individual variability of albuminuria in type 2 diabetes mellitus: implications for categorization of albumin excretion rate. BMC Nephrology, 2017, 18, 355.	0.8	13
78	Effects of glycaemic management on diabetic kidney disease. World Journal of Diabetes, 2017, 8, 172.	1.3	58
79	Assessing cutaneous microvascular function with iontophoresis: Avoiding non-specific vasodilation. Microvascular Research, 2017, 113, 29-39.	1.1	23
80	Progression of Kidney Disease in Indigenous Australians: The eGFR Follow-up Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 993-1004.	2,2	23
81	Insulin pump basal adjustment for exercise in type 1 diabetes: a randomised crossover study. Diabetologia, 2016, 59, 1636-1644.	2.9	66
82	Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2016, 18, 772-783.	2.4	77
83	A Prospective Study of Renal Transplant Recipients: A Fall in Insulin Secretion Underpins Dysglycemia After Renal Transplantation. Transplantation Direct, 2016, 2, e107.	0.8	6
84	Feasibility of an Orthogonal Redundant Sensor incorporating Optical plus Redundant Electrochemical Glucose Sensing. Journal of Diabetes Science and Technology, 2016, 10, 679-688.	1.3	7
85	Elevated baseline glomerular filtration rate (GFR) is independently associated with a more rapid decline in renal function of patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 256-261.	1.2	27
86	Estimating glomerular filtration rate: Performance of the CKD-EPI equation over time in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 49-54.	1.2	20
87	Does a single bout of resistance or aerobic exercise after insulin dose reduction modulate glycaemic control in type 2 diabetes? A randomised cross-over trial. Journal of Science and Medicine in Sport, 2016, 19, 795-799.	0.6	12
88	Associations of serum adiponectin with markers of cardio-metabolic disease risk in Indigenous Australian adults with good health, diabetes and chronic kidney disease. Obesity Research and Clinical Practice, 2016, 10, 659-672.	0.8	6
89	Redundancy in Glucose Sensing. Journal of Diabetes Science and Technology, 2016, 10, 669-678.	1.3	14
90	Cardio-renal protection with empagliflozin. Annals of Translational Medicine, 2016, 4, 409-409.	0.7	19

#	Article	IF	Citations
91	Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with typeÂ2 diabetes mellitus. Clinical Science, 2015, 129, 415-422.	1.8	10
92	The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function. BMC Nephrology, 2015, 16, 198.	0.8	58
93	Liver dysfunction and anti-thyroid therapy. SAGE Open Medical Case Reports, 2015, 3, 2050313X1456833.	0.2	6
94	Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials. Journal of Human Hypertension, 2015, 29, 473-477.	1.0	6
95	Hyperfiltration in Indigenous Australians with and without diabetes. Nephrology Dialysis Transplantation, 2015, 30, 1877-1884.	0.4	12
96	Adding Measures of Body Composition to the CKD-EPI GFR Estimating Equation in Indigenous Australians: The eGFR Study. American Journal of Kidney Diseases, 2015, 65, 632-634.	2.1	3
97	Combining cutaneous silent periods with quantitative sudomotor axon reflex testing in the assessment of diabetic small fiber neuropathy. Clinical Neurophysiology, 2015, 126, 1047-1053.	0.7	15
98	The impact of hyperfiltration on the diabetic kidney. Diabetes and Metabolism, 2015, 41, 5-17.	1.4	84
99	Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140097.	0.2	9
100	The high burden of inpatient diabetes mellitus: the Melbourne Public Hospitals Diabetes Inpatient Audit. Medical Journal of Australia, 2014, 201, 334-338.	0.8	65
101	Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin–angiotensin–aldosterone system. Clinical Science, 2014, 126, 147-154.	1.8	11
102	Spectrum of renal disease in diabetes. Nephrology, 2014, 19, 528-536.	0.7	20
103	Performance of formulas for estimating glomerular filtration rate in Indigenous Australians with and without TypeÂ2 diabetes: the <scp>eGFR</scp> Study. Diabetic Medicine, 2014, 31, 829-838.	1.2	25
104	Prevalence, predictors and evolution of echocardiographically defined cardiac abnormalities in adults with type 1 diabetes: an observational cohort study. Journal of Diabetes and Its Complications, 2014, 28, 22-28.	1.2	27
105	Serum vitamin D levels, diabetes and cardio-metabolic risk factors in Aboriginal and Torres Strait Islander Australians. Diabetology and Metabolic Syndrome, 2014, 6, 78.	1.2	11
106	â€~Progressive diabetic nephropathy. How useful is microalbuminuria?: contra'. Kidney International, 2014, 86, 50-57.	2.6	81
107	Markers of and Risk Factors for the Development and Progression of Diabetic Kidney Disease. American Journal of Kidney Diseases, 2014, 63, S39-S62.	2.1	247
108	New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?. Heart Lung and Circulation, 2014, 23, 997-1008.	0.2	12

#	Article	IF	CITATIONS
109	Renal Structure in Normoalbuminuric and Albuminuric Patients With Type 2 Diabetes and Impaired Renal Function. Diabetes Care, 2013, 36, 3620-3626.	4.3	178
110	Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. Diabetes, 2012, 61, 3304-3313.	0.3	221
111	Accurate Assessment of Kidney Function in Indigenous Australians: The Estimated GFR Study. American Journal of Kidney Diseases, 2012, 60, 680-682.	2.1	40
112	The CTGF gene â^'945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes. Cardiovascular Diabetology, 2012, 11, 42.	2.7	7
113	Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes. Heart Lung and Circulation, 2011, 20, 647-654.	0.2	71
114	Diabetic kidney disease with and without albuminuria. Current Opinion in Nephrology and Hypertension, 2011, 20, 246-257.	1.0	152
115	New approaches for the evaluation of renal vascular function in diabetes. Diabetologia, 2011, 54, 2223-2225.	2.9	0
116	Failure of functional imaging with gallium-68-DOTA-D-Phe1-Tyr3-octreotide positron emission tomography to localize the site of ectopic adrenocorticotropic hormone secretion: a case report. Journal of Medical Case Reports, 2011, 5, 405.	0.4	5
117	Advanced Glycation Urinary Protein-Bound Biomarkers and Severity of Diabetic Nephropathy in Man. American Journal of Nephrology, 2011, 34, 347-355.	1.4	38
118	Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care, 2011, 34, 703-709.	4.3	274
119	Estimating glomerular filtration rate in diabetes using serum cystatin C. Clinical Biochemist Reviews, 2011, 32, 61-7.	3.3	14
120	Salt supplementation blunts the blood pressure response to telmisartan with or without hydrochlorothiazide in hypertensive patients with type 2 diabetes. Diabetologia, 2010, 53, 1295-1303.	2.9	23
121	The clinical significance of hyperfiltration in diabetes. Diabetologia, 2010, 53, 2093-2104.	2.9	177
122	Study Protocol - Accurate assessment of kidney function in Indigenous Australians: aims and methods of the eGFR Study. BMC Public Health, 2010, 10, 80.	1.2	31
123	High sodium and low potassium intake in patients with Type 2 diabetes. Diabetic Medicine, 2010, 27, 1401-1408.	1.2	31
124	Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney International, 2010, 78, 287-295.	2.6	69
125	Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nature Reviews Nephrology, 2009, 5, 397-406.	4.1	84
126	Nonalbuminuric Renal Impairment in Type 2 Diabetic Patients and in the General Population (National) Tj ETQq0 2009, 32, 1497-1502.	0 0 rgBT / 4.3	Overlock 10 T 175

#	Article	IF	Citations
127	Low testosterone and anaemia in men with type 2 diabetes. Clinical Endocrinology, 2009, 70, 547-553.	1.2	53
128	Patterns of glycaemic control in Australian primary care (NEFRON 8). Internal Medicine Journal, 2009, 39, 512-518.	0.5	24
129	Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes. Cardiovascular Diabetology, 2008, 7, 15.	2.7	13
130	New and old markers of progression of diabetic nephropathy. Diabetes Research and Clinical Practice, 2008, 82, S30-S37.	1.1	51
131	Lowering of Proteinuria in Response to Antihypertensive Therapy Predicts Improved Renal Function in Late but Not in Early Diabetic Nephropathy: A Pooled Analysis. American Journal of Nephrology, 2008, 28, 614-627.	1.4	47
132	Serial Measurements of Cystatin C Are More Accurate Than Creatinine-Based Methods in Detecting Declining Renal Function in Type 1 Diabetes. Diabetes Care, 2008, 31, 971-973.	4.3	84
133	Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with TypeÂ2 diabetes. Clinical Science, 2008, 114, 313-320.	1.8	53
134	The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabetic Medicine, 2007, 24, 443-448.	1.2	46
135	Diabetes and the Kidney. , 2006, , 21-47.		1
136	Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clinical Science, 2006, 110, 109-116.	1.8	43
137	Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia, 2006, 49, 1686-1689.	2.9	130
138	Is Nonalbuminuric Renal Insufficiency in Type 2 Diabetes Related to an Increase in Intrarenal Vascular Disease?. Diabetes Care, 2006, 29, 1560-1566.	4.3	124
139	A case of mucormycosis limited to the parotid gland. Head and Neck, 2005, 27, 1108-1111.	0.9	14
140	Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate. Diabetologia, 2005, 48, 2486-2493.	2.9	88
141	Albuminuric and non-albuminuric pathways to renal impairment in diabetes. Minerva Endocrinologica, 2005, 30, 161-77.	1.7	8
142	The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrology Dialysis Transplantation, 2004, 19, 1792-1797.	0.4	98
143	Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. Kidney International, 2004, 65, 1850-1855.	2.6	98
144	Nonalbuminuric Renal Insufficiency in Type 2 Diabetes. Diabetes Care, 2004, 27, 195-200.	4.3	353

#	Article	lF	CITATIONS
145	New insights into the significance of microalbuminuria. Current Opinion in Nephrology and Hypertension, 2004, 13, 83-91.	1.0	44
146	Microalbuminuria and diabetic cardiovascular disease. Current Atherosclerosis Reports, 2003, 5, 350-357.	2.0	9
147	Unrecognized Anemia in Patients With Diabetes: A cross-sectional survey. Diabetes Care, 2003, 26, 1164-1169.	<b>4.</b> 3	291
148	Treatment of Dyslipidaemia in the Elderly. Journal of Pharmacy Practice and Research, 2002, 32, 188-193.	0.5	1
149	Diabetic muscle infarction. Medical Journal of Australia, 2002, 177, 323-324.	0.8	24
150	Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies. Internal Medicine Journal, 2002, 32, 379-385.	0.5	104